Adocia Raises €14M to Boost Protein Chaperone Technology

BioWorld International Correspondent

Adocia SA raised €14 million (US$20.3 million) in a second funding round to continue development of its BioChaperone protein delivery technology, which is designed to prolong the localized activity of growth factors and other protein-based drugs at their sites of action. The company, based in Lyon, France, has filed investigational new drug applications on its first two development programs, and clinical trials are due to begin shortly.

To continue reading subscribe now to BioWorld Asia (formerly International)